- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 26.02. | Changes at the top of Sarepta, Alkermes, as CEOs depart | ||
| 25.02. | Novo Nordisk beefs up in oral obesity drugs with Vivtex deal | ||
| 25.02. | GSK grows pipeline with 35Pharma takeover, Frontier deal | ||
| 25.02. | Novo Nordisk to cut GLP-1 prices in tough US market | ||
| 25.02. | Astellas bets on Vir cancer drug, and other licensing deals | ||
| 25.02. | In brief SOTU remarks, Trump asks Congress to "codify" MFN | ||
| 24.02. | UK spurs prescribing of obesity jab Mounjaro with GP bonus | ||
| 24.02. | After CagriSema blow, Novo reveals data for obesity 'triple' | ||
| 24.02. | Joy as NICE changes tack on first NHS vitiligo treatment | ||
| 24.02. | MSD splits pharma business, hiving off oncology | ||
| 24.02. | FDA maps new regulatory route for ultra-rare diseases | ||
| 23.02. | FDA clears first all-oral combo for first-line CLL treatment | ||
| 23.02. | Gilead buys cell therapy partner Arcellx for up to $7.8bn | ||
| 23.02. | Head-to-head trial dents Novo Nordisk's obesity hopes | ||
| 23.02. | Patients struggling with NHS complexity, says report | ||
| 23.02. | What next for pharma as SCOTUS strikes down Trump tariffs? | ||
| 20.02. | FDA starts review of Regeneron's drug for rare disease FOP | ||
| 20.02. | Grail's multi-cancer test fluffs its lines in UK trial | ||
| 20.02. | UK firm steps in to ease medicine supply crisis in NHS | ||
| 20.02. | Texas sues Sanofi, claiming kickbacks to doctors | ||
| 20.02. | Ex-Novartis CMO John Tsai joins Daiichi Sankyo | ||
| 19.02. | Hims & Hers buys Australian digital health firm for $1.15bn | ||
| 19.02. | Makary says FDA will "end two-trial dogma" for approvals | ||
| 19.02. | NICE backs changes to NHS' diabetes care pathway | ||
| 19.02. | NIH Director Bhattacharya will temporarily run CDC |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.